Ultragenyx Pharmaceutical
RARE
176 hedge funds and large institutions have $4.05B invested in Ultragenyx Pharmaceutical in 2019 Q1 according to their latest regulatory filings, with 30 funds opening new positions, 89 increasing their positions, 31 reducing their positions, and 18 closing their positions.
187% more repeat investments, than reductions
Existing positions increased: 89 | Existing positions reduced: 31
103% more call options, than puts
Call options by funds: $22.7M | Put options by funds: $11.2M
87% more capital invested
Capital invested by funds: $2.16B → $4.05B (+$1.89B)
67% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 18
7% more funds holding
Funds holding: 164 → 176 (+12)
2.09% more ownership
Funds ownership: 100.11% → 102.21% (+2.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
+$55.9M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$55.1M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$44.1M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$41.8M |
| 5 |
Alkeon Capital Management
New York
|
+$37.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$24.5M |
| 2 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
-$18.6M |
| 3 |
D.E. Shaw & Co
New York
|
-$10.2M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$7.55M |
| 5 |
State Street
Boston,
Massachusetts
|
-$7.42M |
RARE Hedge Fund Activity: Q1 2019 in Review
176 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Ultragenyx Pharmaceutical (RARE) for Q1 2019, worth a combined $4.05B — up 87% from $2.16B a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new RARE positions and 18 closed out — a net gain of 12 holders — while 89 added to existing stakes and 31 trimmed.
The largest buyer was Capital International Investors, adding an estimated $55.9M. The largest seller was Fidelity Investments, cutting an estimated $24.5M.
- 176 institutional investors held Ultragenyx Pharmaceutical (RARE) as of Q1 2019, up from 164 in Q4 2018.
- Funds reported $4.05B of Ultragenyx Pharmaceutical stock for Q1 2019, up 87% quarter-over-quarter.
- 30 funds opened new Ultragenyx Pharmaceutical positions in Q1 2019 and 18 closed out, a net change of +12 holders.
- The largest Ultragenyx Pharmaceutical buyer in Q1 2019 was Capital International Investors, an estimated $55.9M added.
- The largest Ultragenyx Pharmaceutical seller in Q1 2019 was Fidelity Investments, an estimated $24.5M sold.
Based on aggregated 13F filings for Q1 2019.